NCT06215755 is a Phase 1 clinical trial of VRG50635 in Amyotrophic Lateral Sclerosis, sponsored by Verge Genomics.

Who is sponsoring NCT06215755?

NCT06215755 is sponsored by Verge Genomics.

What drugs are being tested in NCT06215755?

Interventions in NCT06215755: VRG50635.

What condition does NCT06215755 study?

NCT06215755 studies Amyotrophic Lateral Sclerosis.

Is NCT06215755 still recruiting?

NCT06215755 is currently terminated. Last updated 15 December 2025.

Last reviewed 2025-12-15 · How we verify

NCT06215755

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Terminated Phase 1 Last updated 15 December 2025

What this trial tests

Phase 1 trial testing VRG50635 in Amyotrophic Lateral Sclerosis in 54 participants. Terminated before completion.

Timeline

15 January 2024

Primary endpoint
7 July 2025

7 July 2025

Quick facts

Lead sponsor	Verge Genomics
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	54
Start date	15 January 2024
Primary completion	7 July 2025
Estimated completion	7 July 2025
Sites	7 locations across Belgium, Finland, Canada, Netherlands

Drugs / interventions tested

VRG50635 — full drug profile →

Conditions studied

Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →

Sponsor

Verge Genomics — full company profile →

Who can join

Adults 18 to 74, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Advancements and challenges in amyotrophic lateral sclerosis.
Bradford D, Rodgers KE. · · 2024 · cited 11× · PMID 38846716 · DOI 10.3389/fnins.2024.1401706
Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations.
Quigley SE, Quigg KH, Goutman SA. · · 2025 · cited 2× · PMID 40897992 · DOI 10.1007/s40263-025-01217-0
Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB): A Translational Pharmacodynamic Biomarker for PIKfyve Inhibition With VRG50635.
Gontier G, Kim G, Wang C, Zhu K, et al · · 2026 · PMID 41708347 · DOI 10.1111/cts.70489
Programmable self-replicating JEV nanotherapeutics redefine RNA delivery in ALS.
Loo YS, Yusoh NA, Yap K, Ng CS. · · 2025 · PMID 40858858 · DOI 10.1038/s42003-025-08579-7

Verify or expand the search:

Other trials of VRG50635

Trials testing the same drug.

NCT06286475 — A Study of VRG50635 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07502677 — Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Scle · recruiting
NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting

Other Verge Genomics trials

Trials by the same sponsor.

NCT06286475 — A Study of VRG50635 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06215755 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Verge Genomics
Last refreshed: 15 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06215755.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing